What is the market size of Yersinia Diagnostics Market?

Yersinia Diagnostics Market size was valued at USD 3.33 billion in 2022 and is poised to grow from USD 3.47 billion in 2023 to USD 4.63 billion by 2031, growing at a CAGR of 4.2% in the forecast period (2024-2031).

What is the key driver of Yersinia Diagnostics Market?

Yersinia species, particularly Yersinia enterocolitica and Yersinia pseudotuberculosis, are significant causes of foodborne illness and gastrointestinal infections worldwide. The prevalence of Yersinia infections varies geographically and temporally, but regions with a higher incidence of these infections create a substantial demand for diagnostic tests. As the number of cases increases, healthcare providers and public health authorities require accurate diagnostic tools to identify and manage Yersinia infections effectively.

Yersinia Diagnostics Market Updates

Yersinia Diagnostics Market News

In May 2021, CerTest announced that it has reached the final stage in the extension of its production capacity and the enlargement of the plant located in San Mateo de Gallego, in Zaragoza. In 2021, the company also started working on new production lines for various diagnostic tests.

On March 4, 2024— Abbott, Real Madrid, and the Real Madrid Foundation announced the extension of their partnership through Real Madrid's 2026-27 season. Abbott will remain the Global Health Sciences and Nutrition Partner of Real Madrid Football Club and Global Partner of the Real Madrid Foundation. Abbott and Real Madrid will continue to work together on their shared goal of fostering health and nutrition among children and building a healthier world for generations to come.

On February 14, 2024- GSK plc announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions.

On March 8, 2024-Thermo Fisher Scientific Inc., the world leader in serving science, announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP). This registry, which is open to enrolment, is CorEvitas’ 10th syndicated disease registry and addresses an unmet need for real-world evidence (RWE) related to the clinical and patient-reported outcomes of patients with GPP.

FAQs

Global Yersinia Diagnostics Market size was valued at USD 3.47 billion in 2023 and is poised to grow from USD 3.62 billion in 2024 to USD 5.03 billion by 2032, growing at a CAGR of 4.2% during the forecast period (2025-2032).

The Yersinia diagnostics market has several market players that shape the market share. Among the many major companies, Bio-Rad, Abbott Laboratory, and Thermo Fisher Scientific are the major companies in the market. Companies invest in research and development to innovate and differentiate their diagnostic products. This includes developing novel assays, improving test performance, enhancing automation capabilities, and expanding test menus to address evolving market needs. For example, companies may focus on developing multiplex assays that simultaneously detect multiple Yersinia species or combine Yersinia targets with other pathogens in syndromic panels for comprehensive testing. Marketing efforts may emphasize the unique features, performance benefits, and clinical utility of diagnostic products for Yersinia detection, positioning them as preferred choices among competitors. The Yersinia diagnostics market is competitive, with several companies vying to offer innovative diagnostic solutions for the detection and characterization of Yersinia species. These companies compete based on factors such as technological advancements, product portfolio, pricing, regulatory approvals, distribution networks, and customer support. 'Abbott Laboratories (USA) ', 'Thermo Fisher Scientific (USA) ', 'Bio-Rad Laboratories (USA) ', 'Hologic, Inc. (USA) ', 'Becton, Dickinson and Company (BD) (USA) ', 'Danaher Corporation (USA) ', 'PerkinElmer, Inc. (USA) ', 'QIAGEN N.V. (Netherlands) ', 'F. Hoffmann-La Roche Ltd (Switzerland) ', 'Siemens Healthineers AG (Germany) ', 'bioMérieux SA (France) ', 'Merck KGaA (Germany) ', 'Lonza Group AG (Switzerland) ', 'Agilent Technologies, Inc. (USA) ', 'Illumina, Inc. (USA) ', 'bioAffinity Technologies, Inc. (USA) ', 'Gen-Probe Incorporated (USA) '

Shift Towards Molecular Diagnostics: There is a noticeable trend towards the adoption of molecular diagnostic methods, such as polymerase chain reaction (PCR) assays and nucleic acid amplification tests (NAATs), for Yersinia detection. Molecular methods offer several advantages over traditional culture-based techniques, including higher sensitivity, specificity, and faster turnaround times. They allow for the direct detection of Yersinia DNA in clinical specimens, enabling rapid and accurate diagnosis. As a result, healthcare providers and laboratories are increasingly investing in molecular diagnostic platforms and assays for Yersinia diagnostics, driving market growth in this segment.

North America holds the dominant share in the Yersinia diagnostics market due to the rising incidence of infections. Also, The United States and Canada have well-established healthcare systems and advanced diagnostic capabilities, making North America a significant player in the diagnostics market. Leading diagnostic companies such as Abbott Laboratories, Thermo Fisher Scientific, Inc., and Bio-Rad Laboratories based in North America often develop and distribute a wide range of diagnostic assays, including those for bacterial infections like Yersinia. The region benefits from strong research institutions, clinical laboratories, and regulatory agencies, contributing to the innovation and commercialization of diagnostic products. Public health agencies in North America actively monitor infectious diseases, including Yersinia, driving demand for diagnostic tests and surveillance tools.